Please assess the completion status of the following clinical trial:

Trial Title: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known Sezary Syndrome~* Pruritus uncontrolled by conventional treatment. Baseline visual analogue scale \> 4.~* Age 18 through 80 years of age.~* Stable medication regimens for both Sezary Syndrome and pruritus for 3 months prior to study participation.~Exclusion Criteria:~* Known hepatic impairment (defined as liver function tests \>3 times the upper limit of normal).~* Pregnancy (all women of child-bearing potential will undergo urine beta-hcg testing).~* Concurrent use of pimozide, terfenadine, astemizole, or cisapride.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: ACTIVE_COMPARATOR): Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be given in place of aprepitant

Based on this trial design, predict the completion outcome and termination type (if applicable).